1 active not recruiting, 1 recruiting. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 1, Recruiting 1 |
Follow IVIg-placebo: new trials by email Literature Review of IVIg-placebo trials Research Report on IVIg-placebo
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP empasiprubart, IVIg, empasiprubart-placebo - Chronic Inflammatory Demyelinating Polyneuropathy, CIDP | Phase 3 | Recruiting | argenx | 218 | 2025-08-22 | 2026-10-16 |
| A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy Empasiprubart, IVIG (Intravenous Immunoglobulin), Empasiprubart-placebo - Multifocal Motor Neuropathy (MMN), MMN | Phase 3 | Active not recruiting | argenx | 154 | 2024-12-18 | 2026-09-22 |
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (1)
argenx (2)
Australia (2) · Austria (2) · Brazil (2) · Canada (2) · Czechia (2) · France (2) · Germany (2) · Greece (2) · Italy (2) · Japan (2) · Netherlands (2) · Norway (2) · Poland (2) · Portugal (2) · Serbia (2)